PET/CT Imaging of VTE
Jenny Belsky, DO
Primary Investigator
Brief description of study
What is the purpose of this study?
The primary objective of this study is to assess the prognostic value of PET/CT imaging for predicting venous thromboembolism (VTE) risk in pediatric, adolescent, and young adult (AYA) patients with lymphoma. Investigators at each site will evaluate each clinical case of lymphoma for potential involvement in the study. If the patient meets inclusion criteria, the patient’s imaging and outcomes data will be collected.
THIS STUDY IS ENROLLING BY INVITATION ONLY - Consistent with most oncology trials, patients are not actively “recruited,” but are screened by their physician for appropriate clinical trial(s) at the time of their routine clinic visit. Occasionally, a patient may be a self-referral or physician referral, but are still screened for appropriate clinical trials at the time of their routine clinic visit. PI and staff may send copies of relevant consent forms to these patients to look over prior to actually consenting or enrolling them. This may take place at the patient's visit at which the consent is presented or the patient's next visit to the outpatient hematology/oncology clinic.
Interested in participating? For more information about this research study or other cancer-related clinical trials at IU Simon Comprehensive Cancer Center, please contact:
IU Clinical Trials Office
Email: iutrials@iu.edu
Phone: (317) 278-5632
Detailed description of study
What will happen during the study?
- We will prospectively collect standard of care PET/CT images and clinical outcomes data over
- 4 years from 420 pediatric, adolescent and young adult (AYA) patients (ages 1 – 21 yrs.) who have been diagnosed with lymphomas (Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL)).
- PET/CT Imaging Protocol: Patients with lymphoma diagnoses who undergo PET/CT imaging at initial staging of disease and first treatment follow-up will be included from each site. All patients will undergo a standard 6-hour minimum fasting period prior to PET/CT scans and will be intravenously administered a standard dose of 18F-FDG (0.14 mCi/kg).
- Patients will be required to have a fasting blood glucose value less than 150 mg/dL at the time of dose injection.
- All PET images will be acquired 60±10 minutes after 18F-FDG injection using a standardized acquisition protocol on PET/CT systems. Co-registered CT images will be acquired during each imaging session for PET image attenuation correction
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: Lymphoma, Riley
-
Age: - 21 Years
-
Gender: All
Inclusion Criteria:
• Diagnosis of lymphoma (Hodgkin or Non-Hogkin)
• Underwent routine serial PET/CT imaging during cancer treatment / management
Exclusion Criteria:
• Adults unable to consent
• Individuals who are not yet adults (infants, children, teenagers)
• Pregnant women
• Prisoners
